Concepción Sánchez‐Martínez

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 555 citations · Full text

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel et al. · Drug Metabolism and Disposition · 2015 · 270 citations

Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties

Mary M. Mader, Alfonso de Dios, Chuan Shih et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 114 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Biochemistry +8

Metabolomic and biochemical characterization of a new model of the transition of acute kidney injury to chronic kidney disease induced by folic acid

Marlene Marisol Perales-Quintana, Alma L. Saucedo, J. Ricardo Lucio‐Gutiérrez et al. · PeerJ · 2019 · 38 citations · Full text

Abstract B234: LY2835219, a potent oral inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6) that crosses the blood-brain barrier and demonstrates in vivo activity against intracranial human brain tumor xenografts.

Concepción Sánchez‐Martínez, Lawrence M. Gelbert, Harlan E. Shannon et al. · Molecular Cancer Therapeutics · 2011 · 31 citations

Murine Bbb, Cancer Biology, Glioma +17